



December 5, 2017

Acceleron to Host Conference Call and Webcast to Review Data Presented at the 59th American Society of Hematology Annual Meeting and Exposition

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) will host a conference call and live audio webcast on Monday, December 11, 2017 at 7:00 a.m. EST to review highlights from its Phase 2 clinical presentations at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12, 2017 in Atlanta, Georgia.

Participants can access the live conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and referring to the Acceleron ASH 2017 update.

The live webcast can be accessed on the Investors page of the company's website at www.acceleronpharma.com.

A replay of the webcast will be available approximately two hours after the event on the Acceleron website.

About Acceleron

Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary program with a Phase 2 trial of sotatercept planned in pulmonary arterial hypertension.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: [@AcceleronPharma](https://twitter.com/AcceleronPharma) and [LinkedIn](https://www.linkedin.com/company/acceleron-pharma).

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20171205005546/en/>

Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Vice President, Investor Relations and Corporate Communications
or
Candice Ellis, 617-649-9226
Manager, Investor Relations and Corporate Communications
or
Media:
BMC Communications
Brad Miles, 646-513-3125

Source: Acceleron Pharma

News Provided by Acquire Media